Darunavir/ritonavir (DRV/r) Advocacy!

In December 2021, HIV advocates from around the world demanded access to an optimal second-line medicine called darunavir/ritonavir (DRV/r), which has been used in high-income countries for over 15 years but only just recently became available outside of wealthy nations. Few countries, primarily Nigeria and Zambia, have begun to use DRV/r, but widespread access and availability has not happened yet.

To support advocacy for this product, Afrocab has developed a FAQ (below) that covers the topics of HIV treatment failure and explains how DRV/r works, is taken, and its side effects. Please read and share with your networks so that we can advocate for our brothers and sisters who need second-line treatment!

Published: January 26, 2023